Gibson Dunn Advises BVF Partners L.P. on up to $400 Million Financing for Immunic, Inc.
Tuesday, May 12, 2026 · first reported by Gibson Dunn
Gibson Dunn advised BVF Partners on up to $400M private placement financing for Immunic, a late-stage biotech. Portfolio company funding, not fund raise.
- Firm
- BVF Partners
- Also named
- Gibson Dunn, Immunic, Inc.
- Asset class
- Venture
- Geography
- North America
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
Coverage
1 source- DIG Ventures raises $120m third fund to target Europe’s AI infrastructure startupsAltAssets +1
- Sofia-based LAUNCHub Ventures secures €65 million first close of Fund III; targets €75 million+EU-Startups +4
- Stride Consumer grows fund 30% with $550m hard-cap close after four-month raiseAltAssets +1
- Forty.5 Ventures Closes a $30M First Fund to Move SEE Founders Onto the World StageThe Recursive
- SEC charges Meyer Global Management, CEO with defrauding investors in SpaceX pre-IPO fundPensions & Investments +1
- Two Google alumni raise $11.3M to back AI startups that enterprises will actually pay forTechCrunch +1